Targeting tumour vasculature: the development of combretastatin A4
- 1 February 2001
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 2 (2) , 82-87
- https://doi.org/10.1016/s1470-2045(00)00224-2
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Antiangiogenic Strategies and Agents in Clinical TrialsThe Oncologist, 2000
- Bone Marrow Origin of Endothelial Progenitor Cells Responsible for Postnatal Vasculogenesis in Physiological and Pathological NeovascularizationCirculation Research, 1999
- Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferonNature Medicine, 1999
- Antineoplastic Agents. 379. Synthesis of Phenstatin Phosphate1a,Journal of Medicinal Chemistry, 1998
- Antiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature, 1997
- Mechanisms of angiogenesisNature, 1997
- Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancerInternational Journal of Cancer, 1997
- Vascular endothelial growth factor expression in primary esophageal squamous cell carcinomaCancer, 1997
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisPublished by Elsevier ,1996
- Tumor Angiogenesis: A New Significant and Independent Prognostic Indicator in Early-Stage Breast CarcinomaJNCI Journal of the National Cancer Institute, 1992